Revolutionary software program features first-of-its-kind apps to track test results allowing for quicker returns to work, school and travel, and increased peace of mind
GoMeyra, an innovative new software company dedicated to providing revolutionary tech solutions for medical laboratories, announced today the launch of a customizable cloud-based lab information management system – GoMeyra LIMS.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005321/en/
GoMeyra LIMS was developed as a solution to alleviate bottlenecks and increase efficiency challenges inherent in laboratory workflows. (Photo: Business Wire)
Recognizing the tremendous pressure labs are experiencing to turn around COVID-19 test results, GoMeyra LIMS was specifically designed and developed as a solution to alleviate bottlenecks and increase efficiency challenges inherent in laboratory workflows. By bringing together the bioinformatic expertise of world-class scientists with enterprise-level software engineers, GoMeyra is an unparalleled digital solution for medical laboratories.
On Friday, J.P. Morgan analysts reiterated their Overweight rating on Abbott Laboratories (ABT) while raising their price target from $110 to $125. The analysts give their insight on what they expect to see from 3Q20 results for Abbott Laboratories ahead of earnings season. They like MedTech and Diagnostic businesses combined with BinaxNow, Libre 3.0 and better Fx dynamics.
The analysts forecast 3Q20 revenue sales of $8.70B (+7.8% reported, +8.6%cc) and cash EPS of $0.92 (+9.4%). This is a bit higher than the Street forecast of $8.49B (+7.0%cc) and $0.90 EPS. Similar to the last quarter, better-than-expected COVID trends will work in Abbott’s favor. Medical Devices and Diagnostics is the main factor in representing most of upside given how consensus numbers haven’t moved for recent product announcements (i.e. Binax) and commentary.
J.P. Morgan analysts mentioned, “When combined with the tailwinds the company is seeing within diagnostics from its COVID-19 test approvals,
A study published on Global Microfluidics Technology Market, includes exploratory survey, qualitative commentary on changing market dynamics with market sizing and estimates for 18+ Global Countries, business segments and applications. The identification of hot and emerging players is completed by profiling 50+ Industry players; some of the profiled players are Abbott Laboratories, Perkinelmer, Cepheid, Raindance Technologies, Becton, Dickinson, Bio-Rad Laboratories, Johnson & Johnson, Life Technologies Corporation, Microfluidic Chipshop GMBH & Siemens Healthcare
Get Inside Scoop of the report, request for sample @:https://www.htfmarketreport.com/sample-report/1393262-global-microfluidics-technology-market-3
Latest analysis highlights high growth emerging players and leaders by market share that are currently attracting exceptional attention. It also encourages executives and managers to evaluate deeply complementary research metric. The assessments also offer insight into the share and size of varioussegments in the Microfluidics Technology market. The scope of the study includes market break-up or segmentation as follows:
On Monday, J.P. Morgan and Morgan Stanley reiterated their Overweight ratings on Abbott Laboratories (ABT). The company’s newest continuous glucose monitor (CGM), the Freestyle Libre 3, recently received a CE mark of approval. The system has shown to be a major evolutionary improvement over the current Libre 2 which leads analysts to believe that there are multiple long-term growth opportunities for Abbott.
The next-gen Libre CGM, Libre 3 will leverage Bluetooth technology to have continuous, real-time glucose readings automatically delivered to your smartphone every-minute (vs user scanning required in the past) allowing for unsurpassed 14-day accuracy and a ~70% size reduction from the Libre 1 & 2, becoming the world’s smallest and thinnest sensor.
The FreeStyle Libre 3 system was designed to fit perfectly into people’s everyday lives, allowing users to check their glucose as often as they like by just looking on their phones. This innovation allows the users
Prof. Juan de Pablo has been appointed Vice President for National Laboratories, Science Strategy, Innovation and Global Initiatives at the University of Chicago, effective immediately.
In his new role, de Pablo—currently the Vice President for National Laboratories, the Liew Family Professor in Molecular Engineering and senior scientist at Argonne National Laboratory—will help drive and support the University’s science, technology and innovation efforts, along with their connection to policy and industry. In close consultation with President Robert J. Zimmer, and in close collaboration with Provost Ka Yee C. Lee, deans and faculty, he will help shape emerging strategic scientific and technological initiatives. He also will provide oversight of entrepreneurship and innovation activities at the Polsky Center for Entrepreneurship and Innovation, in close partnership with Madhav Rajan, the dean of Chicago Booth.
De Pablo also will work to build global academic partnerships, extend the reach of the University’s research collaborations with international
A new phase of the modernization of the IAEA’s nuclear application laboratories in Seibersdorf, Austria is required in order to better serve the needs of Member States, speakers said at today’s virtual side event on the margins of the 64th IAEA General Conference.
“Many of our Member States lack the resources to address cancer, pandemics and climate change. They are counting on us to help them,” said IAEA Director General Rafael Mariano Grossi during his opening remarks at the event. “That is why I believe it is imperative that we complete the modernization of the IAEA nuclear applications laboratories — your laboratories — as soon as possible.”
Research on human and zoonotic diseases, cancer treatment and adapting to changing climates through climate smart agriculture are some examples of the work that takes place in the eight IAEA laboratories. Under the Renovation of the Nuclear Applications Laboratory (ReNuAL) Project: Labs Fit